Diagnostics company NanoLogix (OTCBB:NNLX) is preparing several U.S. Food and Drug Administration applications for its rapid bacteria-testing technology.
NanoLogix said the applications will include results of tests that examined the company’s technology in detecting tuberculosis and Group B Streptococcus, according to a statement from the Hubbard, Ohio-based company.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company’s technology involves a proprietary water-permeable cellulose membrane that’s surrounded by a nutrient mix and lays in a petri dish.
Bacteria grows on the membrane, which is then transferred to a staining plate, and allows bacterial microcolonies to become visible more quickly than competing technologies, according to the company.
NanoLogix is working with an unidentified company that will submit the applications to the FDA. “While it takes the time line out of our hands, it frees NanoLogix staff and resources to focus on further research and development of our technologies,” CEO Bret Barnhizer said.
Separately, NanoLogix said it’s developing an antibody for Listeria for use in prescreening food packaging, food processing equipment and preparation surfaces.